VOYA Investment Management
TERN

VOYA Investment Management’s Terns Pharmaceuticals TERN Stock Holding History

VOYA Investment Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-165,562
Closed -$8.73M – 2560
2026
Q1 		$8.73M Buy
165,562
+43,167
+35% +$1.77M 0.01% 664
2025
Q4 		$4.94M Buy
122,395
+108,729
+796% +$2.51M ﹤0.01% 870
2025
Q3 		$103K Sell
13,666
-6,515
-32% -$41.6K ﹤0.01% 2298
2025
Q2 		$75.3K Buy
20,181
+385
+2% +$1.2K ﹤0.01% 2540
2025
Q1 		$54.6K Sell
19,796
-684
-3% -$2.79K ﹤0.01% 2534
2024
Q4 		$113K Buy
20,480
+1,313
+7% +$8.89K ﹤0.01% 2552
2024
Q3 		$160K Sell
19,167
-456
-2% -$3.75K ﹤0.01% 2544
2024
Q2 		$134K Buy
19,623
+5,370
+38% +$32.5K ﹤0.01% 2596
2024
Q1 		$93.5K Sell
14,253
-3,626
-20% -$23.7K ﹤0.01% 2629
2023
Q4 		$116K Hold
17,879
– – ﹤0.01% 2723
2023
Q3 		$89.9K Buy
17,879
+783
+5% +$4.97K ﹤0.01% 2758
2023
Q2 		$150K Buy
+17,096
New +$199K ﹤0.01% 2681

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

VOYA Investment Management's TERN Position: Q2 2026 in Review

VOYA Investment Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 165,562 shares — an estimated $8.73M sold.

VOYA Investment Management first reported a position in TERN in Q2 2023 and held it in 12 quarters. The position peaked at $8.73M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • VOYA Investment Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • VOYA Investment Management sold 165,562 Terns Pharmaceuticals shares in Q2 2026, an estimated $8.73M.
  • VOYA Investment Management first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 12 quarters.
  • VOYA Investment Management's Terns Pharmaceuticals position peaked at $8.73M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.